aTyr Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of aTyr Pharma generated cash of -$33,220,999, which is more than the previous year. Cash used in financing activities reached the amount of $66,230,000 last year. Net change in cash is therefore $12,563,000.
Cash Flow
| 2014 | -22.82M | -2.24M | 2.51M |
|---|---|---|---|
| 2015 | -36.79M | -71.99M | 147.91M |
| 2016 | -52.86M | 33.52M | 4.69M |
| 2017 | -42.36M | -27.63M | 52.70M |
| 2018 | -31.06M | 37.17M | -4.23M |
| 2019 | -20.01M | 4.92M | 1.33M |
| 2020 | -15.30M | 6.9M | 16.14M |
| 2021 | -33.07M | -91.56M | 110.02M |
| 2022 | -41.88M | 47.24M | 5.45M |
| 2023 | -33.22M | -20.12M | 66.23M |
LIFE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.98M | 2.33M | 16.95M | 9.21M | 22.96M | 21.09M | 38.38M | 53.02M | 13.89M | 36.45M |
Operating activities | ||||||||||
Net income | -50.38M | -45.34M | -33.77M | -16.23M | -23.76M | -34.51M | -48.20M | -57.85M | -47.97M | -24.35M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.74M | 1.69M | 1.30M | 1.26M | 1.36M | 746K | 713K | 900K | 869K | 829K |
Stock-based compensation expense | 2.6M | 2.15M | 1.61M | 1.46M | 1.78M | 0 | 6.78M | 5.02M | 4.85M | 1.79M |
| Deferred income tax benefit | 2.6M | 2.15M | 1.61M | 1.46M | 1.78M | 0 | 6.78M | 5.02M | 4.85M | 1.79M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 9.05M | -11.92M | 1.60M | -1.93M | 58K | -53K | 0 | 0 | 0 | 0 |
Inventories | 0 | 11.92M | 0 | 1.93M | -58K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 3.26M | 6.74M | 47K | 1.76M | 162K | -2.05M | -2.49M | -932K | 3.94M | 0 |
Cash generated by operating activities | -33.22M | -41.88M | -33.07M | -15.30M | -20.01M | -31.06M | -42.36M | -52.86M | -36.79M | -22.82M |
Investing activities | ||||||||||
Purchases Of Investments | -106.97M | -42.11M | -126.50M | -21.06M | -40.64M | -40.29M | -77.67M | -28.08M | -109.44M | -5.39M |
Investments In Property Plant And Equipment | -4.21M | -1.64M | -192K | -202K | -79K | -594K | -1.31M | -600K | -664K | -249K |
Acquisitions Net | 15K | 179K | 50K | 18K | 51K | -261K | 14K | 531K | 0 | 0 |
Cash generated by investing activities | -20.12M | 47.24M | -91.56M | 6.9M | 4.92M | 37.17M | -27.63M | 33.52M | -71.99M | -2.24M |
Financing activities | ||||||||||
Common Stock Issued | 66.62M | 5.51M | 110.02M | 6.44M | 9.33M | 379K | 42.47M | 143K | 76.90M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 105K | 0 | 0 | 0 | 0 | 36K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -9.08M | 0 | -4.66M | 0 | -5.20M | 0 | -1.56M |
Cash used in financing activities | 66.23M | 5.45M | 110.02M | 16.14M | 1.33M | -4.23M | 52.70M | 4.69M | 147.91M | 2.51M |
Net Change In Cash | 12.56M | 10.81M | -14.61M | 7.74M | -13.75M | 1.87M | -17.29M | -14.63M | 39.12M | -22.55M |
Cash at end of period | 22.54M | 13.14M | 2.33M | 16.95M | 9.21M | 22.96M | 21.09M | 38.38M | 53.02M | 13.89M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |